Abstract: This disclosure relates to novel modified oligonucleotides. Novel modified siRNA are also provided.

Abstract: Novel oligonucleotides that enhance silencing of the expression of a gene containing a single nucleotide polymorphism (SNP) relative to the expression of the corresponding wild-type gene are provided. Methods of using novel oligonucleotides that enhance silencing of the expression of a gene containing a SNP relative to the expression of the corresponding wild-type gene are provided.

Abstract: In various embodiments, degradation of epoxy within packages for ultraviolet light-emitting devices is reduced or substantially eliminated via package venting, prevention of transmission of ultraviolet light to one or more regions of epoxy utilized in the package, and/or utilization of packaging schemes that reduce or avoid utilization of epoxy and/or specific metals.

Abstract: A motor controller includes a first control circuit, a second control circuit, a determination circuit, and a command circuit. The first control circuit outputs a first control value based on a rule base from a command value of an angular velocity and a measured value of an angular velocity. The second control circuit outputs a second control value based on a learned model from the command value of the angular velocity and the measured value of the angular velocity. The determination circuit determines a state based on at least the second control value. The command circuit acquires and outputs a control command value from the first control value and the second control value based on a result determined by the determination circuit.

Abstract: An optical cable includes: twisted optical fiber units each including a fiber group formed by optical fibers. At least one of the optical fiber units includes a filling that wraps an outer circumference of the fiber group.

Abstract: The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3: wherein R1, R2, R3, R4, Ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as GDF15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease/steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders.

Abstract: A natural gas liquefying apparatus includes: a precooling unit, which is a treatment unit configured to precool natural gas; a liquefying unit, which is a treatment unit configured to liquefy the natural gas; a refrigerant cooling unit, which is a treatment unit configured to cool a liquefying refrigerant; a compression unit configured to compress vaporized refrigerants; and a pipe rack including air-cooled coolers arrayed and arranged on an upper surface. The treatment units and the compression unit are separately arranged in a first arrangement region and a second arrangement region arranged opposed to each other across a long side of the pipe rack. The pipe rack interposed between the first and second arrangement regions has a region in which no air-cooled cooler is arranged in order to arrange a plurality of pipes, through which refrigerants are allowed to flow, in a direction of a short side of the pipe rack.

Abstract: Novel oligonucleotides that enhance silencing of the expression of a gene containing a single nucleotide polymorphism (SNP) relative to the expression of the corresponding wild-type gene are provided. Methods of using novel oligonucleotides that enhance silencing of the expression of a gene containing a SNP relative to the expression of the corresponding wild-type gene are provided.

Abstract: This disclosure relates to novel modified oligonucleotides. Novel modified siRNA are also provided.

Abstract: Novel oligonucleotides that enhance silencing of the expression of a gene containing a single nucleotide polymorphism (SNP) relative to the expression of the corresponding wild-type gene are provided. Methods of using novel oligonucleotides that enhance silencing of the expression of a gene containing a SNP relative to the expression of the corresponding wild-type gene are provided.

Abstract: This disclosure relates to novel SARS-CoV-2 targeting sequences. Novel SARS-CoV-2 targeting oligonucleotides for the treatment of SARS-CoV-2 infection are also provided.

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Abstract: Described herein are bifunctional degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment of conditions, diseases, and disorders mediated by various target proteins.

Abstract: One variation of a method for secure and distributed timekeeping includes: at a node in a set of nodes in a network, at a first time, sampling two time sources and calculating a minor consensus time between the two time sources; in response to designation of the node as a leader node, accessing a second minor consensus time generated by a second node, accessing a third minor consensus time generated by a third node, calculating a first major consensus time between the first, second, and third minor consensus times, and distributing a request to validate the first major consensus time; and, based on validation of the request from a threshold quantity of nodes, cryptographically hashing a hash of a previous block and the major consensus time to generate a first block and distributing the first block to each node in the set of nodes.

Abstract: Described herein are glue degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment or prevention of conditions, diseases, and disorders mediated by various target proteins.

Abstract: One variation of a method for secure and distributed timekeeping includes: at a node in a set of nodes in a network, at a first time, sampling two time sources and calculating a minor consensus time between the two time sources; in response to designation of the node as a leader node, accessing a second minor consensus time generated by a second node, accessing a third minor consensus time generated by a third node, calculating a first major consensus time between the first, second, and third minor consensus times, and distributing a request to validate the first major consensus time; and, based on validation of the request from a threshold quantity of nodes, cryptographically hashing a hash of a previous block and the major consensus time to generate a first block and distributing the first block to each node in the set of nodes.

Abstract: Provided is a rear vehicle-body structure of a vehicle, capable of reducing vibrations transmitted from a rear wheel to a floor panel, while ensuring required performance for rear side frames and a cross member. The rear vehicle-body structure comprises a symmetric pair of frame members extending in a vehicle longitudinal direction along respective lateral sides of a rear of a vehicle body of the vehicle, and a rear-side rear cross member bridging the symmetric pair of frame members in a vehicle width direction, wherein an attachment portion between each of the frame members and the rear-side rear cross member provided with rigidity difference generation part to generate a rigidity difference between the frame member and the rear-side rear cross member.

Abstract: This disclosure relates to the synthesis of novel modified oligonucleotides. The synthesis of novel phosphoramidites are also provided.

Abstract: This disclosure relates to novel modified oligonucleotides with increased stability. The universal modified nucleotide sequences to increase the stability of an oligonucleotide are also provided.

Abstract: Chemically modified crRNAs and tracrRNAs are provided. crRNAs and tracrRNAs with 5? and/or 3? conjugated moieties are provided. crRNAs and tracrRNAs with modifications in the repeat region of the crRNA or the anti-repeat region of the tracrRNA are provided. Methods of using the crRNAs and tracrRNAs for genome editing with a CRISPR nuclease and kits for performing the same are also provided.